ReviewMaterials today. Bio2026
Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), brain tumors, and stroke, remain difficult to treat due to the restrictive nature of the blood-brain barrier (BBB). Traditional Chinese medicine (TCM) bioactive compounds offer multitarget therapeutic potential, but their clinical translation is limited by poor solubility, instability, rapid clearance, and insufficient brain exposure. Nanodelivery systems can enhance pharmacokinetics and enable brain-targeted delivery via engineered nanocarriers that exploit multiple BBB-crossing routes. This review summarizes nanotechnology-based strategies that facilitate efficient BBB transport, targeted brain accumulation, and microenvironment-responsive release of TCM-derived bioactives. Emphasis is placed on rational nanocarrier design, including biomimetic surface modification, physicochemical optimization, multicomponent integration, and stimulus-responsive systems that improve spatiotemporal control and therapeutic precision. Collectively, these strategy-oriented principles provide a translational framework for advancing nano-enabled TCM therapeutics in complex brain disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.